Clinical Trials · NCT04767594
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
- Phase
- N/A
- Recruitment status
- Active Not Recruiting
- Sponsor
- Pfizer
- Enrollment
- 1,407
- Start date
- Oct 2020
- Locations
- 192 sites, Austria, Germany
- Primary endpoint
- Progression-free survival (PFS)